KOSDAQBiotech & Pharma183490

Enzychem Lifesciences

₩990 0.00%2026-10-02 close

Market Cap

₩83.8B

Turnover

₩0

Volume

0 shares

Shares out.

84.6M

PER

—

PBR

0.6×

EPS

-₩230

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Persistent Losses Amid Bio-Oil and EC-18 Dual Tracks

Enzychem Lifesciences operates two core tracks—the EC-18 drug candidate pipeline and subsidiary Shinheung Mulsan's bio-oil (HVO/SAF feedstock) business—but has posted operating losses in each of the last four fiscal years, steadily eroding its financial cushion.

1
2025 revenue fell year-on-year to KRW 67.7bn, marking a fourth consecutive year of operating losses
2
Q1-Q2 2026 revenue showed sequential recovery, though net losses persisted
3
EC-18 oral mucositis Phase 2 results published in an international journal; company preparing FDA breakthrough designation and Phase 3 IND
4
The bio-oil segment saw profitability deteriorate due to raw material supply constraints and rising SG&A
5
Shareholders' equity has continuously shrunk since 2022, reflecting accumulated losses

Business structure

Enzychem Lifesciences operates four business segments: global new drug development, active pharmaceutical ingredients (API), health functional foods, and bio-oil.

The global drug development segment is centered on its proprietary compound EC-18, with clinical and non-clinical studies targeting chemoradiation-induced oral mucositis, acute radiation syndrome, and atopic dermatitis.

The API segment exports products such as erdosteine, gadobutrol, and D-cycloserine to markets including China, India, Russia, and the UK.

The health functional food segment manufactures and sells products such as 'Rockpid Immune,' based on the company's proprietary deer-antler-derived PLAG ingredient, and the company began exporting to China in 2024 through partnerships including the China-Asia Economic Development Association's elderly service industry committee.

The bio-oil segment, run through subsidiary Shinheung Mulsan, produces feedstock for next-generation biodiesel (HVO) and sustainable aviation fuel (SAF); the unit obtained ISCC international sustainability certification in 2024 and supplies major domestic refiners.

The company has also made an equity investment in TargetLink Therapeutics, an ADC/DAC drug developer, to diversify its pipeline into new modalities, and is expanding through an affiliate structure branded 'EL Group' alongside Medfood, Shinheung Mulsan, and Messena.

However, some industry reports point out that among the 13 EC-18-based pipeline programs, several—including a voluntarily discontinued neutropenia program and an effectively halted COVID-19 program—have stalled.

On the competitive front, the company states that the bio-oil business benefits from limited new entrants due to the difficulty of obtaining comprehensive waste-recycling permits.

Earnings trend

Quarterly revenue · Operating profit

₩16.4B-₩3.7B25Q2₩16.5B-₩3.7B25Q3₩14.1B-₩4.4B25Q4₩14.9B-₩3.2B26Q1₩23.5B-₩4.1B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩26.6B-₩14.7B2022₩76B-₩14.4B2023₩77.4B-₩13.2B2024₩67.8B-₩14.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩16.4B	-₩3.7B	−22.4%
2025Q3	₩16.5B	-₩3.7B	−22.6%
2025Q4	₩14.1B	-₩4.4B	−31.1%
2026Q1	₩14.9B	-₩3.2B	−21.8%
2026Q2	₩23.5B	-₩4.1B	−17.3%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩26.6B	-₩14.7B	-₩25.1B	−55.0%	−12.4%	22.7%
2023	₩76B	-₩14.4B	-₩9.3B	−18.9%	−4.8%	8.7%
2024	₩77.4B	-₩13.2B	-₩22.1B	−17.1%	−13.8%	12.5%
2025	₩67.8B	-₩14.3B	-₩18.1B	−21.2%	−13.2%	7.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Annual revenue rose sharply from KRW 26.6bn in 2022 to KRW 76.0bn in 2023, edged up further to KRW 77.4bn in 2024, but declined to KRW 67.8bn in 2025.

Operating losses persisted across all four years—KRW -14.7bn (2022), -14.4bn (2023), -13.2bn (2024), and -14.3bn (2025)—with the operating margin worsening to -21.2% in 2025 from -17.1% in 2024.

Owner-attributable net loss swung from a large KRW -25.1bn in 2022 to a narrower KRW -9.3bn in 2023, widened again to KRW -22.1bn in 2024, and then narrowed somewhat to KRW -18.1bn in 2025.

On a quarterly basis, Q3 2025 posted revenue of KRW 16.5bn, an operating loss of KRW -3.7bn, and an owner net loss of KRW -3.3bn; Q4 2025 saw revenue slip to KRW 14.1bn while the operating loss widened to KRW -4.4bn and the owner net loss expanded sharply to KRW -9.9bn, likely reflecting one-off items.

Q1 2026 showed revenue of KRW 14.9bn with a narrower operating loss of KRW -3.2bn and a sharply reduced net loss of KRW -1.9bn versus the prior quarter. Q2 2026 revenue rose noticeably to KRW 23.5bn quarter-on-quarter, but the operating loss widened again to KRW -4.1bn with a net loss of KRW -2.9bn.

Over the trailing four quarters (Q3 2025-Q2 2026), cumulative revenue was roughly KRW 69bn with a cumulative owner net loss of around KRW 18bn, indicating revenue recovery and loss reduction have not moved in tandem.

On the cash flow side, operating cash flow was a relatively modest KRW -0.6bn in 2024 but widened again to KRW -11.0bn in 2025, contributing to the continuous decline in shareholders' equity from KRW 201.7bn in 2022 to KRW 137.5bn in 2025.

Industry analysis

According to market research cited in company disclosures, the oral mucositis treatment market was valued at roughly USD 1.5bn in 2020 and is projected to grow at a 4.0% CAGR to approximately USD 1.8bn by 2026, a niche market affecting about 40% of chemoradiation patients and up to 90% of head and neck cancer patients.

No approved standard treatment currently exists in this space, and the efficacy data EC-18 generated in its Phase 2 trial is expected to inform the decision on whether to proceed to Phase 3.

The acute radiation syndrome (GI-ARS) field is a specialized market driven by government stockpiling demand for nuclear or radiological accident response, structurally characterized by the difficulty of conducting conventional human trials given the absence of any approved treatment.

The bio-oil (HVO/SAF feedstock) market is expected to see expanding demand driven by policy tailwinds such as the EU's sustainable aviation fuel blending mandates, with the comprehensive waste-recycling permit requirement in Korea cited as a factor limiting new competitive entry.

In the health functional food market, rising demand for elderly health management products amid China's aging population has been cited as the backdrop for the company's export expansion.

Overall, the company appears to have diversified its revenue base into non-drug businesses such as bio-oil and health foods to mitigate the risk associated with a single drug candidate, forming a relatively distinctive position among listed Korean biotechs.

Outlook

The company has stated it is preparing an FDA breakthrough therapy designation (BTD) application and a Phase 3 IND for EC-18's oral mucositis indication, based on efficacy and safety data confirmed in its US Phase 2 trial.

In the acute radiation syndrome (GI-ARS) field, a joint research effort with the Korea Institute of Radiological and Medical Sciences (KIRAMS) completed a preliminary rodent-model study in February 2026, with plans confirmed to further evaluate gut-protective effects and mechanisms of action in mid-size animal models that are physiologically closer to humans.

In August 2026, the company also announced a joint development effort with KIRAMS for a radiation dermatitis treatment.

The bio-oil segment is pursuing capacity expansion and overseas market entry into Europe and China, according to the company, though as of Q1 2026 profitability in the segment actually deteriorated due to raw material supply difficulties and rising SG&A.

The health functional food segment is working to expand export volumes of Rockpid to China, while the API segment needs to improve profitability after being affected by health insurance reimbursement reassessments.

The company also stated it continues collaborating with TargetLink Therapeutics, in which it has invested to expand into ADC/DAC modalities, alongside ongoing AI-based drug discovery platform and Cenotherapeutics research.

While numerous clinical and business events are on the horizon, specific timelines and outcomes remain unconfirmed.

Valuation

PER

—

PBR

0.6×

ROE

-12.0%

EPS

-₩230

BPS

₩1,795

Dividend per share

₩0

The company has posted net losses in each of the past four fiscal years, making earnings-based valuation metrics difficult to compute. From a price-to-book perspective, with shareholders' equity having continuously declined due to accumulated losses, the shares trade in a range below per-share net asset value.

As there has been no recent dividend track record, the dividend-yield appeal can be characterized as limited.

That said, these metrics could shift meaningfully depending on the outcome of the clinical pipeline or a recovery in bio-oil segment profitability, so the current figures alone should not be read as a definitive judgment on business quality.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Peer-Reviewed Validation of EC-18 Clinical Data

EC-18's US Phase 2 results were published in the oncology journal 'Cancers,' with co-authors including a Harvard School of Dental Medicine professor.

In the maximum tolerated dose group, the median duration of severe oral mucositis was reduced by 100% versus placebo, and the company has cited this data as the basis for preparing an FDA breakthrough therapy designation and Phase 3 IND.

Given the absence of an approved standard treatment for this indication, further development progress could open a path to establishing a market position.

Policy Tailwinds for the Bio-Oil Business

Subsidiary Shinheung Mulsan produces feedstock for next-generation biodiesel (HVO) and sustainable aviation fuel (SAF) and obtained ISCC international certification in 2024.

It supplies feedstock directly to major domestic refiners, and the company states that the comprehensive waste-recycling permit requirement limits new competitor entry. Tightening global regulations, such as the EU's sustainable aviation fuel blending mandate, could translate into expanding demand.

Diversified Revenue Base and New Modality Investment

The company has partially mitigated single-drug-candidate risk through its API, health functional food, and bio-oil businesses, and its 'Rockpid' health food product is attempting to enter the Chinese elderly-population market.

It has also made an equity investment in ADC/DAC developer TargetLink Therapeutics to expand pipeline modalities. This diversified structure could reduce the extent to which overall company value hinges on a single clinical outcome.

Bear factors

Four Consecutive Years of Operating Losses and Cash Burn

The company posted operating losses every year from 2022 through 2025, and operating cash flow was negative by double-digit billions of won in every year except 2024. Over this period, shareholders' equity continuously declined from KRW 201.7bn in 2022 to KRW 137.5bn in 2025. No clear signal of a near-term improvement in this loss structure has yet been confirmed.

Market Criticism of Pipeline Stagnation

Some media outlets have pointed out that while the company has announced 13 EC-18-based pipeline programs, most have shown no updates since Phase 1 or have effectively been discontinued.

The neutropenia treatment program was voluntarily halted, and the COVID-19 treatment program is understood to have effectively stopped. The oral mucositis program has also previously failed to secure FDA breakthrough therapy designation, making it difficult to predict the outcome of the renewed attempt.

Deteriorating Profitability in Bio-Oil and API Segments

As of Q1 2026, the bio-oil segment's profitability is understood to have deteriorated due to raw material supply difficulties and rising SG&A expenses. The API segment also saw revenue decline for certain items due to the impact of health insurance reimbursement reassessments.

Since both segments account for a substantial portion of company revenue, delayed improvement could have a significant impact on overall results.

Risk factors

Financial Risk

With shareholders' equity declining each year amid ongoing accumulated losses, further capital raising may become necessary if losses continue. Depending on the method of fundraising, there is a risk of dilution to existing shareholders.

Clinical and Regulatory Risk

The FDA breakthrough therapy designation and Phase 3 IND have not yet been confirmed as filed or approved, and there is a past instance where a similar designation attempt was unsuccessful.

The acute radiation syndrome indication must navigate a specialized regulatory pathway given the difficulty of conventional human efficacy verification.

Segment-Level Business Risk

The bio-oil business is structurally exposed to raw material supply conditions such as waste cooking oil and to changes in ISCC and EU policy.

Health functional food exports are exposed to relationships with Chinese partner organizations and local regulatory changes, leaving persistent earnings volatility from external factors.

What to watch next

Around mid-November 2026
The Q3 2026 quarterly report is expected around this time; it is worth checking whether the bio-oil and API segments show a profitability recovery and whether the revenue recovery trend continues.
In the second half of 2026
It is worth monitoring whether results from the mid-size animal model study for acute radiation syndrome (GI-ARS), conducted jointly with KIRAMS, are announced.
From Q4 2026 onward
Whether an FDA breakthrough therapy designation application and a Phase 3 IND submission for the EC-18 oral mucositis indication are filed, and their outcomes, should be checked.
From Q4 2026 onward
Progress on the follow-up research for the radiation dermatitis treatment jointly developed with KIRAMS, announced in August 2026, should be checked.

Overall view

Enzychem Lifesciences has a diversified revenue structure spanning its EC-18-based drug pipeline and its bio-oil, health functional food, and API businesses, but it has recorded operating losses every year from 2022 through 2025, leaving it with a financial structure marked by continuously shrinking equity.

Revenue showed a sequential recovery in Q1 and Q2 2026, but net losses have continued, so it would be premature to conclude the company has fully emerged from its loss structure.

EC-18's oral mucositis Phase 2 data has been published in an international journal, giving it an academic basis, and the company states it is preparing an FDA breakthrough therapy designation and Phase 3 IND, but this process remains incomplete and there is a past instance where a similar designation attempt was unsuccessful.

The bio-oil business carries expectations of policy-driven demand expansion, but the most recent quarterly data showed profitability actually deteriorating due to raw material supply issues.

On balance, the company faces two parallel sources of uncertainty—clinical pipeline progress and segment-level profitability recovery—and its direction will need to be confirmed through future disclosures and clinical result announcements.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.